Elias Tu, who brings a solid track record leadership that facilitates patient outcomes, has joined Dublin, Ireland-based Mainstay Medical Holdings as Vice President of U.S. Sales
Elias Tu: New VP of Sales at Mainstay Medical
1 min read Premium comments
Secondary#mainstaymedical#eliastu
“Prior to his new role at Mainstay, Elias Tu served as global commercial leader in the neurology division at Philips Healthcare,” said the news release. “He also has over 13 years of sales experience at LivaNova, a medical device company specializing in devices used for cardiac surgery and neuromodulation. From 2016 to 2019, Mr. Tu served as Vice President of Sales for Neuromodulation in North America at LivaNova where he attained $350 million in annual sales.”
Commenting on their spate of new hires was Mainstay CEO Jason Hannon, who said, “We continue to demonstrate the clinical value ReActiv8 brings to patients and are preparing to expand the availability of this compelling therapy in multiple countries. Each of these individuals brings incredible leadership and experience to help build our commercial capabilities, expand in our existing markets, and launch in the U.S. Each of them is experienced in bringing disruptive new technologies to the market and will help us deliver ReActiv8 to patients suffering from mechanical chronic low back pain and the physicians treating this condition. Collectively they complement the existing strong leadership we already have and will leverage the deep history of clinical and scientific leadership we’ve developed.”
Elias Tu told OTW, “My initial focus is building out our dedicated sales force to launch this novel and effective therapy in the U.S. Physicians have so few options for treating patients with chronic mechanical low back pain, and I’m looking forward to building a commercial team of clinical experts who support these physicians in bringing needed relief and functional improvement to their patients.”
“Elias has an impressive track record in launching novel neuromodulation therapies and he thoroughly understands that the supportive clinical relationships between us and the physicians is what ultimately supports great patient outcomes,” stated Jason Hannon to OTW.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.